Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan and dye aim to spot lung cancer more precisely during surgery

NCT ID NCT07498933

Diagnosis Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special PET/CT scan (FAPI-PET/CT) and a fluorescent dye can better predict how well lung cancer responds to pre-surgery therapy and help surgeons see tumors during operation. 200 adults with stage II-IIIB non-small cell lung cancer will receive the scan and dye before surgery. The goal is to improve accuracy in finding cancer tissue, which could lead to more complete removal of tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FAPI-PET/CT scan and fluorescent dye
What this could lead to
If successful, this could lead to more accurate tumor detection during lung cancer surgery, helping surgeons remove all cancer cells while sparing healthy tissue.
What could go wrong
This is an early diagnostic study, not a treatment. The imaging technique may not prove more accurate than current methods, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with lung cancer who plan to receive neoadjuvant immunotherapy combined with chemotherapy

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 70 years old; * Have complete clinical and imaging data; * Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer; * Able to retain sufficient tumor tissue for testing and research; * Sign informed consent. Exclusion Criteria: * Previously combined with other malignant tumors or received other anti-tumor treatments; * Failure to collect sufficient tumor tissue for testing and research; * The duration of neoadjuvant therapy is less than 3 cycles; * The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing; * Lack of clinical and imaging data; * There are situations where other researchers consider it inappropriate to participate in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoadjuvant therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoadjuvant therapy Non-small cell lung cancer Pet / CT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.